Clinical trial · Observational
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
NCT02586844CI-TRIAL-00057809NET-SEQcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective study to obtain fresh tumor biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumors (NETs) or well-differentiated pancreatic neuroendocrine tumors (PanNETs) for molecular profiling.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Pancreatic Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Neuroendocrine tumors (NETs)
- description
- Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
- label
- panNETs
- description
- Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
Primary outcomes (1)
- measure
- To prospectively collect tumor tissue and blood sample from patients with carcinoid tumors and islet cell tumors.
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- To evaluate gene alterations differences between carcinoid tumors and islet cell tumors.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years. * Histological or cytological proof of NETs or PanNETs. * At least one biopsiable lesion deemed medically accessible and safe to biopsy. * Current/recent treatment with targeted therapies with confirmed clinical benefit; confirmed progression disease to targeted therapies at the time of study enrollment. * Fulfills local institution's laboratory parameters for tumor biopsy. * Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: * Any condition that could interfere with their ability to provide informed consent such as dementia or severe cognitive impairment. * Any contraindication to undergoing a biopsy or blood collection procedure.
References
Publications (0)
Data not yet available
No reference posted for this study.